ALNY
Alnylam Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$266.11
+0.61%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-12.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Jun 3, 2026 | PYOTT DAVID E I · director | Sale | 1,175 | $299 |
| Jun 3, 2026 | PYOTT DAVID E I · director | Sale | 495 | $301 |
| Jun 3, 2026 | PYOTT DAVID E I · director | Sale | 1,222 | $300 |
| Jun 3, 2026 | PYOTT DAVID E I · director | M-Exempt | 3,830 | $0.00 |
| Jun 3, 2026 | PYOTT DAVID E I · director | Sale | 17 | $303 |
| Jun 3, 2026 | Cravatt Benjamin · director | A-Award | 4,393 | $296 |
| Jun 3, 2026 | PYOTT DAVID E I · director | Sale | 921 | $298 |
| May 22, 2026 | HAMBURG MARGARET A · director | A-Award | 1,441 | $298 |
| May 22, 2026 | BRANDICOURT OLIVIER · director | A-Award | 671 | $0.00 |
| May 22, 2026 | Ausiello Dennis A · director | A-Award | 1,441 | $298 |
| May 22, 2026 | Ausiello Dennis A · director | A-Award | 671 | $0.00 |
| May 22, 2026 | Arbuckle Stuart A · director | A-Award | 671 | $0.00 |
| May 22, 2026 | SCHULMAN AMY W · director | A-Award | 1,802 | $298 |
| May 22, 2026 | Sigal Charles Elliott · director | A-Award | 671 | $0.00 |
| May 22, 2026 | KELLOGG PETER N · director | A-Award | 671 | $0.00 |
| May 22, 2026 | BRANDICOURT OLIVIER · director | A-Award | 1,441 | $298 |
| May 22, 2026 | Reitan Colleen F · director | A-Award | 671 | $0.00 |
| May 22, 2026 | PYOTT DAVID E I · director | A-Award | 671 | $0.00 |
| May 22, 2026 | Arbuckle Stuart A · director | A-Award | 1,441 | $298 |
| May 22, 2026 | PYOTT DAVID E I · director | A-Award | 1,441 | $298 |
| May 22, 2026 | Reitan Colleen F · director | A-Award | 1,441 | $298 |
| May 22, 2026 | SCHULMAN AMY W · director | A-Award | 838 | $0.00 |
| May 22, 2026 | KELLOGG PETER N · director | A-Award | 1,441 | $298 |
| May 22, 2026 | HAMBURG MARGARET A · director | A-Award | 671 | $0.00 |
| May 22, 2026 | Sigal Charles Elliott · director | A-Award | 1,441 | $298 |
| May 14, 2026 | SCHULMAN AMY W · director | M-Exempt | 11,250 | $70 |
| Apr 7, 2026 | McLaughlin Melissa · officer: Chief Human Resources Officer | Sale | 209 | $318 |
| Apr 7, 2026 | McLaughlin Melissa · officer: Chief Human Resources Officer | Sale | 81 | $324 |
| Apr 7, 2026 | McLaughlin Melissa · officer: Chief Human Resources Officer | Sale | 56 | $320 |
| Apr 7, 2026 | McLaughlin Melissa · officer: Chief Human Resources Officer | Sale | 8 | $325 |
Institutional positioning
13F filings over the trailing two quarters
New 194Increased 639Reduced 556Sold out 86
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 15,023,962 | Aug 13, 2026 |
| FMR LLC | Reduced | 14,579,166 | May 15, 2026 |
| Capital World Investors | Increased | 11,144,846 | Aug 12, 2026 |
| BlackRock, Inc. | Increased | 10,907,675 | Aug 7, 2026 |
| CAPITAL WORLD INVESTORS | Reduced | 10,802,348 | May 13, 2026 |
| BLACKROCK, INC. | Increased | 10,444,908 | May 13, 2026 |
| Capital Research Global Investors | Increased | 9,750,699 | Aug 12, 2026 |
| CAPITAL RESEARCH GLOBAL INVESTORS | Increased | 9,471,181 | May 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | Increased | 6,538,390 | Aug 13, 2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | New Position | 6,491,280 | May 8, 2026 |
| JPMORGAN CHASE & CO | Increased | 6,323,752 | May 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 6,029,478 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 5,946,706 | May 15, 2026 |
| T. Rowe Price Investment Management, Inc. | Increased | 5,642,173 | Aug 14, 2026 |
| T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | Increased | 5,193,324 | May 15, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Jun 3, 2026